Trending...
- IDEMIA Awarded 10-Year Blanket Purchase Agreement from the General Services Administration for Next-Generation Identity Proofing for Login.Gov - 315
- Sarah Novotny Joins Kosai as a Board Advisor: A New Chapter for Open Source Leadership
- NY Implant Dentistry - Dr. Greg R. Diamond, DDS – Your Trusted Dentist in NYC, New York
NEW YORK, Jan. 2, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Arvinas, Inc. ("Arvinas" or the "Company") (NASDAQ: ARVN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Arvinas and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On November 19, 2024, Arvinas disclosed in a filing with the U.S. Securities and Exchange Commission that Arvinas and its partner, Pfizer, Inc., decided to postpone the projected completion date for their jointly conducted Phase 3 trial for the breast cancer therapy vepdegestrant "from November 2024 to January 2025, with top-line data anticipated in the first quarter of 2025."
More on Nyenta.com
On this news, Arvinas's stock price fell sharply during intraday trading on November 19, 2024.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980
SOURCE Pomerantz LLP
The investigation concerns whether Arvinas and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On November 19, 2024, Arvinas disclosed in a filing with the U.S. Securities and Exchange Commission that Arvinas and its partner, Pfizer, Inc., decided to postpone the projected completion date for their jointly conducted Phase 3 trial for the breast cancer therapy vepdegestrant "from November 2024 to January 2025, with top-line data anticipated in the first quarter of 2025."
More on Nyenta.com
- Exciting News: Gourmet Meal Kiosks Coming to Wilmorite Malls in Rochester, NY!
- Holistic Energy Bodyworks Launches New Website to Transform Wellness
- Yonkers: HOLLYWOOD ON HUDSON: YONKERS FILM AND TELEVISION PRODUCTION SOARS IN 2024
- Genuine Hospitality, LLC Expands Leadership Team with Key Appointments
- TilePix x Jonathan Adler Introduce The Jet Set Collection
On this news, Arvinas's stock price fell sharply during intraday trading on November 19, 2024.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980
SOURCE Pomerantz LLP
Filed Under: Business
0 Comments
Latest on Nyenta.com
- Doctor at St. Lawrence Psychiatric Center Under Investigation by Office of Professional Misconduct
- Boeing's Commercial Airline AS9100 Delay, FAA Self-Certification, Fatal Crashes, And Conflicts Exposed: By QA Expert Daryl Guberman
- Top Book Printer in Central Ohio announces expansion
- Growth Marshal Publishes New Article on SaaS Lead Generation: "Switch Up Your Approach wit
- NYC Bagpipes Performs for The Traitors TV Show Stunt
- Comp-U-Floor ERP to Showcase All-in-One Flooring Software at TISE 2025
- "Cannabis Industry Dream Team" Launches GreenFlow Systems to Revolutionize Manufacturing Standards
- NYC Wheelchair Transportation Expands 24/7 Accessible Transportation Services Across NYC Metro Area
- V Deadline: V Investors Have Opportunity to Lead Visa Inc. Securities Fraud Lawsuit Filed by The Rosen Law Firm
- Rochester Fire Department Civil Service Exam Applications Now Open
- Pawganja Token: Redefining Cryptocurrency with Transparency and Philanthropy
- Overhaul Secures $55 Million in Funding Led by Springcoast Partners to Accelerate AI Innovation and Strategic Growth
- Investor Workshop at Mar-A-Lago, $27 Million for Acquisitions and Drug Treatment of Suicidal Depression: NRx Pharmaceuticals, Inc. (Stock S: NRXP)
- The Best Places to Go in Mexico in 2025
- Nayarit: Mexico's Best-Kept Secret for Fall and Winter Getaways in 2025
- LIB: A master of ingenuity in the field of custom test chambers, unlocking unlimited possibilities!
- Anatomage Announces Acquisition of Cloud-based Software Company BioDigital
- PRP Aviation Earns Prestigious "Platinum Cirrus Training Center" Designation
- SHAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger - SDIG, IPXX, KAVL, ML
- New Rochelle Job Fair at City Hall, Wednesday, January 22